SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Catalyst Pharmaceuticals, Inc. (CPRX) trades at a trailing P/E of 14.4, forward P/E of 14.2. Trailing earnings yield is 6.95%, forward earnings yield 7.06%. PEG 0.51 (Peter Lynch undervalued ≤1.0). Graham Number is $17.54.
Criteria proven by this page:
- VALUE (84/100, Pass) — P/E is below market average (14.4); PEG ≤ 1.0 — Peter Lynch undervalued (0.51); analyst target implies upside (+26%); earnings yield beats bond yields (6.95%).
- Forward P/E 14.2 (down from trailing 14.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.51 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.95% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 7.06% as earnings recover.
- Analyst consensus target $33.00 (+26% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 92/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
84/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CPRX
Valuation Multiples
P/E (TTM)14.4
Forward P/E14.2
PEG Ratio0.51
Forward PEG1.42
P/B Ratio3.23
P/S Ratio5.26
EV/EBITDA7.6
Per Share Data
EPS (TTM)$1.75
Forward EPS (Est.)$1.85
Book Value / Share$7.80
Revenue / Share$4.82
FCF / Share$1.71
Yields & Fair Value
Earnings Yield6.95%
Forward Earnings Yield7.06%
Dividend Yield0.00%
Graham Number$17.54
SharesGrow IV$50.75 (+93.8%)
Analyst Target$33.00 (+26%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-4.8 |
0.40 |
2.21 |
0.00 |
- |
| 2017 |
-18.2 |
4.01 |
4.14 |
0.00 |
- |
| 2018 |
-5.8 |
-0.10 |
3.88 |
394.11 |
- |
| 2019 |
12.1 |
-0.06 |
4.41 |
3.77 |
- |
| 2020 |
4.6 |
0.03 |
2.04 |
2.90 |
- |
| 2021 |
17.7 |
-0.38 |
3.38 |
4.97 |
- |
| 2022 |
23.1 |
0.21 |
6.40 |
8.98 |
- |
| 2023 |
25.0 |
-1.54 |
4.61 |
4.49 |
- |
| 2024 |
15.1 |
0.14 |
3.40 |
5.03 |
- |
| 2025 |
13.3 |
0.50 |
2.99 |
4.85 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.22 |
$0.00 |
$-18.07M |
- |
| 2017 |
$-0.21 |
$0.00 |
$-18.41M |
- |
| 2018 |
$-0.33 |
$500K |
$-34M |
-6800.7% |
| 2019 |
$0.30 |
$102.31M |
$31.88M |
31.2% |
| 2020 |
$0.71 |
$119.07M |
$74.98M |
63% |
| 2021 |
$0.37 |
$140.83M |
$39.48M |
28% |
| 2022 |
$0.75 |
$214.2M |
$83.08M |
38.8% |
| 2023 |
$0.63 |
$398.2M |
$71.41M |
17.9% |
| 2024 |
$1.31 |
$491.73M |
$163.89M |
33.3% |
| 2025 |
$1.68 |
$588.99M |
$214.33M |
36.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.85 |
$1.68 – $2.02 |
$630.63M |
$624.33M – $634.19M |
4 |
| 2027 |
$2.15 |
$1.91 – $2.35 |
$696.91M |
$678.23M – $711.71M |
4 |
| 2028 |
$2.24 |
$1.89 – $2.58 |
$765.93M |
$765.91M – $765.94M |
2 |
| 2029 |
$2.50 |
$2.38 – $2.57 |
$843.73M |
$812.4M – $862.3M |
1 |
| 2030 |
$2.70 |
$2.57 – $2.78 |
$894.35M |
$861.14M – $914.03M |
1 |
